A new class of drug called siRNA, a cousin of mRNA, can enter cells and stop a specific gene from producing a harmful protein. This enables highly targeted treatments, such as new drugs that reduce a type of cholesterol by over 95% with a single, long-lasting injection.

After decades of work, small interfering RNA (siRNA) has overcome delivery challenges to become a mature, "de-risked" platform, primarily for liver-directed targets. This now enables powerful medicines like a once-yearly injection for high cholesterol, representing a major public health breakthrough.

The failure of Novartis's antisense drug Pella Carson, contrasted with the potential success of Amgen's siRNA targeting the same pathway, could have a profound negative impact on the entire antisense field, favoring siRNA technology for large population diseases.

The approvals of two different oligonucleotide constructs for the same indication (Arrowhead's siRNA vs. IONIS's ASO) mark a significant milestone. This direct competition between RNA modalities signifies a maturing market where companies now focus on determining which molecule is superior for specific targets.

In multiple instances where siRNA and ASO (antisense) therapies have been developed for the same indication, the siRNA drug has emerged with a superior overall profile across efficacy, safety, and dosing convenience. This pattern suggests siRNA is solidifying its position as the more advantageous modality.

While its massive Phase 3 trial for an antisense drug was ongoing, Novartis licensed an siRNA targeting the same LP(a) pathway from a Chinese company. This proactive move suggests Novartis was either building a next-generation follow-on or, more likely, hedging its bets due to a lack of internal confidence in its lead asset's modality.

The commercial advantage of one-time CRISPR/Cas9 therapies is shrinking. Advancements in RNA modalities like siRNA now offer durable, long-lasting effects with a potentially safer profile. This creates a challenging risk-reward calculation for permanent gene edits in diseases where both technologies are applicable, especially as investor sentiment sours on CRISPR's long-term safety.

The industry is on the cusp of a seismic therapeutic shift. Major Phase 3 readouts for siRNA/ASO in common diseases are expected in the next year. Simultaneously, in vivo CAR-T for autoimmunity represents a move from treating symptoms to potentially curing diseases, a true revolutionary step.

Even while its antisense drug Pella Carson was in a major Phase 3 trial, Novartis proactively licensed a competing siRNA technology for the same target. This suggests a sophisticated hedging strategy or internal doubts about the original drug's prospects, a move made years before the trial's failure.